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INTRODUCTION
Cancer is the most prevalent cause of death in developed coun-
tries. Although the advancement in cancer therapy improved sur-
vival rates, radiotherapy and chemotherapy treatments cause sev-
eral side-effects including some in the oral cavity. Oral mucositis
that manifests as inflamed erosive or ulcerative lesions of the oral
mucosa, is currently considered as a severe complication of anti -
cancer therapy, affecting 40-80% of patients undergoing chemo-
therapy (1). Pain associated with oral mucositis can restrain pa-
tients from eating, thus resulting in a major impact on the quality of
life in such patients.
A number of Kampo medicines have been used clinically for the
treatment of various disease ; interestingly, 148 kinds of Kampo
medicinal formula are approved and reimbursed by Japan’s National
Health Insurance (2). However, few Kampo medicines have been
proposed for diseases affecting the oral cavity. Rikkosan has
been suggested for controlling pain after tooth extraction, while
Hangeshashinto, Orento and Inchinkoto may be effective against
stomatitis (3, 4). Among them, Hangeshashinto was used topically,
in addition to an oral intake. Moreover, several in vitro studies on
the beneficial effects of Kampo medicines against periodontal dis-
ease have been published. For instance, it has been reported that
specific Kampo medicines possess anti - inflammatory potential by
reducing the secretion of pro- inflammatory cytokines by host cells
(3-6), in addition to prevent biofilm formation (6) and to inhibit
the growth and the adherence properties of important periodontopa-
thogenic bacteria, including Porphyromonas gingivalis and Fuso-
bacterium nucleatum (7).
Historically, mucositis has been considered to result exclusively
from damage to basal epithelial cells induced by chemotherapy or
chemoradiotherapy. Nowadays, a five-stage model for the patho-
biology of oral mucositis is widely accepted ; this model incorpo-
rates complex interactions among multiple components (8) These
include direct damage to basal epithelial cells from cancer ther-
apy as well as secondary insults to tissue caused by an upregula-
tion of pro- inflammatory mediator production (9). Ulcerative oral
mucositis exposed to the oral microbiota may be complicated by a
localized infection, thus providing a potential route for systemic
sepsis (9).
In order to minimize the harmful effects associated with oral
mucositis, the search for novel potent molecules is of interest.
Natural compounds exhibiting anti - inflammatory and antimicro-
bial properties may represent potentially interesting molecules for
the prevention or treatment of ulcerative lesions of oral tissue. Very
few clinical studies investigated the potential of Kampo medicines
with regard to oral mucositis and mucosal inflammation (10, 11).
Hangeshashinto was effective for the treatment of oral ulcer (4)
and it is covered by the Japanese insurance. In addition, it demon-
strated in our previous study that Daiokanzoto possessed the pre-
ventive effect on 5-FU induced human gingival cell death (12).
The aim of this study was to investigate the impact of the use of
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two Kampo medicines (Daiokanzoto and Hangeshashinto) on oral
mucositis, tongue coating bacteria, and gingiva condition in pa-
tients with esophageal cancer undergoing chemotherapy.
METHODS
Study participants
Twenty- four patients aged from 52 to 81 years-old (21 males
and 3 females, mean age, 64.77.7 years), who received chemo-
therapy with weekly docetaxel, and low dose 5-FU and CDDP
(DFP therapy) as the first regimen specified for esophageal
cancer at the Tokushima University Hospital (13, 14) from June,
2012 to July, 2015 were initially enrolled in the study. The patients
with severe infection, onset of severe complication and allergy
against drug were excluded from this study. Prior to enroll the
participants, they were informed about the methods and objectives
of the study and they provided a written informed consent. This
study was single-center randomized clinical trial. Eligible partici-
pants were randomly divided into three groups using the envelop
method without a blind technique ; seven subjects were given
Daiokanzoto sherbets (TJ-84) (2), seven subjects were given
Hangeshashinto sherbets (TJ-14) (2), and ten subjects were
assigned to the control group. The placebo treatment was not con-
ducted in this study. The Kampo sherbets were made by dissolving
the Kampo formula in distilled H2O, which were poured in a plastic
dish and then frozen until used. The participants consumed sher-
bet containing 2.5 g of Kampo formula three times per day between
meals during the chemotherapy.
Clinical parameters
The chemotherapeutic drug used, the treatment period, the sys-
temic condition, including the presence of fever and blood test
results, were obtained from the patient medical record. The National
Cancer Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE) for oral mucositis was used in this study. The highest
grade of oral mucositis in each patient during the observation pe-
riod was recorded from the medical record or the nursing record in
addition to an oral examination according to NCI-CTCAE version 4
criteria as follows : Grade 1 : asymptomatic or mild symptoms :
intervention not indicated, Grade 2 : moderate pain not interfering
with oral intake ; modified diet indicated, Grade 3 : severe pain in-
terfering with oral intake, Grade 4 : life - threatening consequence ;
urgent intervention indicated, Grade 5 : death. As clinical parame-
ters of the oral cavity, the salivary flow rate, Plaque index (PlI),
Gingival index (GI) (15) and Tongue coating index (TCI) (16) were
recorded. Collection of saliva samples were performed under resting
condition in the afternoon at least 2 h after eating and drinking.
Subject were asked to collect saliva in their mouths and to spit it
into a 50 ml polypropylene conical tube with a diameter of 3 cm for 5
min (17). Oral mucosal humidity (%) was determined by using an
oral moisture checker (MucusTM, Life Co., Koshigaya city, Saitama
prefecture, Japan).
Assessment of clinical parameters, tongue coating sampling, and
professional oral healthcare (POHC) intervention
Assessment of clinical parameters in subjects, including salivary
flow rate, moisture measurement, GI, PlI and TCI was performed
by a dentist before and after chemotherapy, and every week during
the observation period. The measurement and collection of tongue
coating bacteria were also performed at the same day, at least 2 h
after breakfast or lunch to avoid any influence related to eating. A
dental hygienist performed the POHC weekly that includes oral
prophylaxis with toothbrush and inter -dental brush followed by
debridement with hand scaler and by cleaning with 0.1% H2O2
cotton ball. Oral healthcare guidance for self -care was also pro-
vided at every visit at patient bed-site.
The Dielectrophoretic impedance measurement apparatus for
quantification of bacteria (Bacterial CounterTM, Panasonic, Osaka,
Japan) was used to assess tongue coating bacteria according to the
manufacturer’s instructions. Tongue coating samples were col-
lected using sterile 5 mm-diameter cotton stick by swabbing the
tongue dorsum 3 times from back to front (approx. 2-cm-long
swabbing motions). Samples were suspended in 5 ml of distilled
water in disposable cup and bacterial quantification with Bacterial
CounterTM was performed. Thereafter, the samples were dispensed
into vials and kept at -80 until used.
Tongue coating samples were also used to quantify three peri-
odontopathogenic bacteria (Porphyromonas gingivalis, Fusobacterium
nucleatum and Campylobacter rectus) by quantitative PCR as previ-
ously reported by Amou et al (18). with slight modifications. The
MiniOpticon system (Bio-Rad Laboratories, Hercules, CA, USA)
with SYBR Green I dye was used for the quantitative PCR analysis.
One hundred eighty microliter of InstaGene Matrix (Bio-Rad
Laboratories) was added to 20 μl of each tongue coating sample.
The mixtures were incubated at 56 for 30 min, vortexed for 30 s,
incubated at 100 for 8 min, and then stored at -20 until used
for the quatitative PCR analysis. Prior to analysis, the mixtures
were thawed and centrifuged at 10,000 g for 10 min at 4. The
supernatant of the samples was used for DNA template and was
added (2 μl) to the PCR reaction mixture (18 μl) made of 10 μl of
SsoFastTM EvaGreen Supermix (Bio-Rad Laboratories), 0.04 μl of
100 μM of primers (Forward, Reverse) and 7.92 μl of diethylpy-
rocarbonate- treated water. The liquid mixtures were heat- treated
as follows : initial denaturation step (3 min at 95), followed by
denaturation (5 s at 95), annealing (10 s at 60) and extension
(10 s at 60). The number of cycles for P. gingivalis, F. nucleatum
and C. rectus were 45, 38 and 38, respectively. The primers used
for the quantitative PCR have been previously described (19).
Three endpoints were measured in this study. The primary end-
point was to determine the efficacy of Kampo medicine for reduc-
ing the incidence of severe oral mucositis when compared to the
control. The other endpoints were to evaluate oral hygiene and oral
condition, especially, alternation of the number of oral bacteria and
gingival inflammation.
Statistical analysis
The statistics package of IBM SPSS Statistics ver. 20.0 software
(IBM SPSS Japan Inc, Tokyo, Japan) was used to analyze the data.
One-way analysis of variance (ANOVA) was used to compare the
clinical value from the three groups at baseline. A two-way re-
peated measures ANOVA was used to assess the effect of Kampo
treatment on the number of bacteria, moisture measurement, GI,
PlI and TCI. Tukey’s post hoc test were performed for comparison
within groups after a significant Kampo group x observation period
interaction. Values of p0.05 were considered as statistically sig-
nificant.
Ethics
The Ethics Committee of Tokushima University Hospital ap-
proved this study (Approval # : 1920).
RESULTS
Baseline characteristics
One patient in the control group was excluded from the study
because of the onset of an aspiration pneumonia prior the first
week of examination following the chemotherapy period. Table 1
summarizes the demographic variables and clinical parameters at
baseline for each patient group. No significant difference of items at
baseline was found between patients among the three groups
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(control group, n = 9 ; Daiokanzoto group, n = 7 ; Hangeshashinto
group, n = 7) by the analysis of one-way ANOVA.
Onset of oral mucositis associated with chemotherapy
The onset of oral mucositis in the three patient groups during the
chemotherapy is reported in Table 2. Six patients did not complete
the chemotherapy treatments. Five subjects showed mucositis at
grade 2 or more, and oral mucositis lesions were observed on the
lower labial mucous, angulus oris, palate and tongue (data no
shown). A subject with severe pain (grade 3) that interfered with
oral intake was observed in the Hangeshashinto group. No differ-
ence in the onset of slightly and/or severe mucositis was observed
among the three groups.
Comparison of the numbers of bacteria
Fourteen subjects completed the 2-week period of Kampo sher-
bet intake following chemotherapy. Tongue coating samples were
collected at baseline, 1 week and 2 weeks after chemotherapy.
Figure 1 and Table 3 reports the variations in the numbers of total
bacteria during the observation period for patients consuming or
not the Daiokanzoto sherbets. Table 3 shows a statistically signifi-
cant decrease in the number of total bacteria (p0.05), F. nu-
cleatum (p0.01) and C. rectus (p0.05) in both the control
group and the Daiokanzoto group during the full observation pe-
riod. There were significant decreases in those value at 1 week
and 2 weeks within the Daiokanzoto group by a Tukey’s post hoc
test (Fig. 1). Furthermore, a two-way repeated measures ANOVA
showed that the numbers of F. nucleatum and C. rectus in the control
and Daiokanzoto groups were not similar across the observation
period (Kampo group x observation period interaction, p0.05).
These results suggest that the consumption of Daiokanzoto causes a
significant decrease in the numbers of F. nucleatum and C. rectus
compared with the control group. Although the numbers of P. gin-
givalis tended to decrease following Daiokanzoto intake, the differ-
ence was not significant (Fig. 1). A statistically significant de-
crease in the numbers of F. nucleatum (p0.05) in both the control
and Hangeshashinto groups across the observation period was
also observed (Table 3). However, no significant difference was
observed between the control and Hangeshashinto groups.
Comparison of clinical parameters
Analysis of variance of the index in intervention groups (Daiokan-
zoto or Hangeshashinto sherbet intake) compared to the control
group with regard to the clinical parameters during the observation
period is shown in Table 4. While no significant differences were
observed for values of salivary rate and moisture (data no shown), a
statistically significant decrease of TCI (p0.01), GI (p0.01) and
PlI (p0.05) in both the control and Daiokanzoto groups across
the observation period was recorded (Table 4). There were sig-
nificant decreases in the value of TCI and GI within both Daiokan-
zoto group and the control group by post hoc test (Fig. 2). Further-
more, a two-way repeated measures ANOVA showed that GI was
reduced significantly more in the Daiokanzoto group compared
with the control group during the observation period (Table 4). A
statistically significant decrease of TCI (p0.01) and GI (p0.05)
values in both the control group and the Hangeshashinto group
was observed during the observation period. However, the values
between the control group and the Hangeshashinto group were not
significantly different (Table 4).
DISCUSSION
This study clearly showed that the numbers of F. nucleatum
and C. rectus were decreased significantly in patients consuming
Daiokanzoto sherbets when compared with those in the control
group during the early stage of chemotherapy. This result was
similar with Fukamachi et al. who reported the antimicrobial ac-
tivity of Hangeshashinto against 19 oral bacteria includingF.
nucleatum and P. gingivalis (20). Moreover, the Kampo medicine
Rokumigan prevented biofilm formation by F. nucleatum (6). Re-
cently, our group showed that Kampo medicines containing rhu-
barb have the ability to inhibit the growth and virulence proper-
ties of P. gingivalis (7). Daiokanzoto contains rhubarb-derived
Table 1 Items and parameters associated to patient groups at baseline.
Item or parameter Control group Daiokanzoto group Hangeshashinto group
Number of subjects (male : female) 9 (8 : 1) 7 (5 : 2) 7 (7 : 0)
Age 61.87.9 67.18.3 66.66.2
Salivary flow rate (ml/5 min) 2.661.69 3.091.63 1.830.81
Tongue Coating Index (TCI : %) 43.319.3 42.919.7 45.328.2
Moisture measurement 27.24.7 25.23.2 26.73.4
Gingival Index (GI) 1.370.66 1.451.05 1.440.48
Plaque Index (PlI) 1.130.73 1.121.05 1.070.48
Total bacteria (log [cells/ml]) 6.370.57 6.830.36 6.550.75
P. gingivalis (log [cells/ml]) 1.962.35 1.011.74 0.631.67
F. nucleatum (log [cells/ml]) 4.901.87 5.760.90 5.710.76
C. rectus (log [cells/ml]) 3.412.05 4.700.48 3.362.43
Table 2 Highest grade of oral mucositis observed in patients.
Maximum grade of oral mucositis#
No more than
Grade 1 Grade 2 Grade 3
Control group 8(1) 1 0
Daiokanzoto group 6(3) 1(1) 0
Hangeshashinto group 4 2(1) 1
Total 18 4 1
# : Evaluated by NCI-CTCAE Ver. 4.0
Parenthesis means the number of patient who was not completed on a
course of chemotherapy
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molecules, including anthraquinones, which exhibit antibacterial
activity towards several oral bacterial pathogens (7, 21, 22) as
well as synergistic effects against methicillin-resistant Staphylococ-
cus aureus when combined with antibiotics (23, 24). Therefore,
anthraquinone in Daiokanzoto may contribute to decrease the
numbers of F. nucleatum and C. rectus.
In this study, TCI, GI and PlI values decreased during the observa-
tion period. These results suggested that POHC was effective for
improving oral hygiene and gingival condition in patients with
esophageal cancer during chemotherapy. Especially, GI was de-
creased significantly in the Daiokanzoto group when compared with
that in the control group. Interestingly, it has been previously
Fig. 1 Numbers of bacteria in tongue coating from patients with or without intake of Daiokanzoto sherbets. Date are express as meanstandard error.
Asterisk indicates a significant difference of values within group compared with those at baseline,* : p0.05,** : p0.01. a : total bacteria, b : F .
nucleatum, c : C. rectus, d : P. gingivalis
Table 3 Analysis of variance of the numbers of bacteria in Kampo intervention groups compared to control group.
Daiokanzoto group Hangeshashinto group
Index F -value Degree offreedom P -value F -value
Degree of
freedom P -value
Total bacteria Kampo group 0.31 1 0.58 0.01 1 0.91
Observation period 4.84 1.43 0.03* 1.11 1.41 0.3
Kampo group × Observation period 1.72 1.43 0.21 0.47 1.41 0.85
P. gingivalis Kampo group 2.62 1 0.13 0.71 1 0.41
Observation period 2.98 2 0.07 1.37 2 0.27
Kampo group × Observation period 0.61 2 0.55 1.87 2 0.17
F. nucleatum Kampo group 0.88 1 0.36 0.04 1 0.85
Observation period 7.28 2 0.01** 4.57 1.25 0.04*
Kampo group × Observation period 4.26 2 0.02* 3.46 1.25 0.07
C. rectus Kampo group 0.12 1 0.73 0.12 1 0.74
Observation period 5.68 2 0.01* 1.54 2 0.23
Kampo group × Observation period 4.38 2 0.02* 0.75 2 0.48
Two-way repeated measures ANOVA, * : p0.05, ** : p0.01
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demonstrated that Daiokanzoto reduces the secretion of pro- infla-
mmatory cytokines (IL-6 and CXCL8) by LPS-stimulated oral epi-
thelial cells and gingival fibroblasts, and inhibits the catalytic ac-
tivity of matrix metalloproteases (25). This ability of Daiokanzoto
to attenuate the host inflammatory response may be involved in
the reduction of gingival inflammation observed in this study.
Regarding the anti - inflammatory property of Kampo formulas,
Rikkosan has been reported to inhibit both IL-1β and PGE2 produc-
tion (26). Moreover, Shosaikoto decreases LPS-induced PGE2 pro-
duction through inhibition of both cyclogenase-2 expression and
activity (5), while Juzentaihoto effectively inhibits restraint stress
and osteoclastogenesis involved in periodontal tissue destruction
Table 4 Analysis of variance of the clinical parameters in Kampo intervention groups compared to control group.
Daiokanzoto group Hangesyashinto group
Index F -value Degree offreedom P -value F -value
Degree of
freedom P -value
TCI Kampo group 0.01 1 0.92 0.60 1 0.45
Observation period 33.00 2 0.01** 18.00 2 0.01*
Kampo group × Observation period 1.72 2 0.26 0.93 2 0.27
GI Kampo group 0.04 1 0.84 0.47 1 0.51
Observation period 22.20 2 0.01** 7.35 1.19 0.02*
Kampo group × Observation period 3.74 2 0.04* 0.93 1.19 0.61
PlI Kampo group 0.18 1 0.68 1.39 1 0.27
Observation period 4.29 2 0.03* 1.32 1.34 0.29
Kampo group × Observation period 0.95 2 0.40 0.21 1.34 0.73
Two-way repeated measures ANOVA, * : p0.05, ** : p0.01
Fig. 2 Clinical parameters of patients with or without intake of Daiokanzoto sherbets. Date are express as meanstandard error. Asterisk indicates a
significant difference of values within group compared with those at baseline, * : p0.05, ** : p0.01. a : TCI, b : GI, c : PlI
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(27). Lastly, we also showed in a previous study that Rokumigan
inhibits the IL-6 secretion by LPS-stimulated gingival epithelial
cells and fibroblast, in addition to promote wound healing in a fibro-
blast model (6).
In a previous in vitro study, we showed that Daiokanzoto attenu-
ates 5-FU-induced cell death through the inhibition of mitochon-
drial ROS production (12). However, in this study we could not
show any preventive effect of Daiokanzoto on the onset of oral mu-
cositis. Similarly, Hangeshashinto which has been proposed to
treat oral mucositis (11) and found to suppress the mechanical
pain in ulcerative oral mucosa in a rat model (28), did not provide
benefits in this clinical trial. It may be hypothesized that POHC
provided to all subjects has a preventive effect against the onset of
severe oral mucositis. This is supported by the previously reported
efficacy of regular POHC in reducing the risk to develop oral mu-
cositis in breast cancer patients undergoing chemotherapy in com-
parison with a self -oral care group (29).
It has been reported by Oyama et al. (30) that authors developed
the ice ball or freeze cotton swabs containing kampo medicine and
found that they were useful for reducing oral pain in cancer pa-
tients. We designed the sherbet form to simulate the effect for
topical use of Kampo medicine by taking slowly in addition to intake
per orally. Thisclinical trial suggests that Daiokanzoto provided as
sherbets has the potential to prevent gingival inflammation and
reduce the numbers of tongue coating bacteria, including impor-
tant perodontopathogenic bacteria. The major limitation of this
study relates to the small number of subject in each group. In
order to clarify the preventive effects of Kampo medicines for oral
mucositis, it may be relevant to include an additional control group
with self -oral care.
CONCLUSION
This clinical trial did not demonstrate a preventive effect of
Kampo medicine on the onset of mucositis in patients receiving
POHC during chemotherapy for esophageal cancer. However, it
suggests that the use of Daiokanzoto may provide a beneficial
effect for the oral health of patients under chemotherapy for
esophageal cancer, by attenuating the gingival inflammation and
reducing the numbers of periodontopathogenic bacteria.
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